Company: KROS
Filing Date: 2025-04-18
Form Type: 8-K
Source: 0001664710-25-000038
Chunk: 0

Company: Keros Therapeutics, Inc.
Filing Date: 2025-04-18
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item 1.01

Entry into a Material Definitive Agreement.

On April 17, 2025, Keros Therapeutics, Inc. (the “ Company”) entered into a letter agreement (the “ Letter Agreement”) with Pontifax (Israel) IV, L. P., Pontifax (Cayman) IV, L. P., Pontifax (China) IV, L. P. and Pontifax Late Stage Fund L. P. (together with their affiliates, “ Pontifax”).

The Letter Agreement provides that, among other things, the Company will nominate each of Mary Ann Gray, Ran Nussbaum and Alpna Seth, each of whom is a current member of the Company’s Board of Directors, for election at the Company’s 2025 Annual Meeting of Stockholders (the “ Annual Meeting”). In addition, Pontifax has agreed to abide by certain customary standstill restrictions, which remain in effect until the earlier of (x) December 31, 2025 or (y) the thirtieth day prior to the notice deadline under the Company’s Amended and Restated Bylaws (as in effect on the date of the Letter Agreement) for the nomination of director candidates by a stockholder for the Company’s 2026 Annual Meeting of Stockholders, subject to earlier termination in certain limited circumstances as set forth in the Letter Agreement. The Company and Pontifax have also agreed to certain non-disparagement obligations.

The foregoing description does not purport to be complete and is qualified in its entirety by reference to the full text of the Letter Agreement, a copy of which is attached hereto as Exhibit 10.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.